Sorrento Therapeutics, Inc. Quarterly Costs and Expenses in USD from Q3 2013 to Q2 2023

Taxonomy & unit: us-gaap: USD
Description: Total costs of sales and operating expenses for the period.
Summary: Sorrento Therapeutics, Inc. quarterly/annual Costs and Expenses history and growth rate from Q3 2013 to Q2 2023.
Sorrento Therapeutics, Inc. Costs and Expenses for the quarter ending June 30, 2023 was $92.3M, a 28.9% decline year-over-year.
Sorrento Therapeutics, Inc. Costs and Expenses for the twelve months ending June 30, 2023 was $527M, a 6.19% increase year-over-year.
Sorrento Therapeutics, Inc. annual Costs and Expenses for 2022 was $567M, a 24.8% increase from 2021.
Sorrento Therapeutics, Inc. annual Costs and Expenses for 2021 was $454M, a 59.7% increase from 2020.
Sorrento Therapeutics, Inc. annual Costs and Expenses for 2020 was $285M, a 2.17% decline from 2019.

Costs and Expenses, Trailing 12 Months (USD)

Costs and Expenses, Quarterly (USD)

Costs and Expenses, YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q2 2023	$527M	$92.3M	-$37.6M	-28.9%	Apr 1, 2023	Jun 30, 2023	10-Q	2023-08-14
Q1 2023	$564M	$123M	-$2.67M	-2.13%	Jan 1, 2023	Mar 31, 2023	10-Q	2023-05-15
Q4 2022	$567M	$185M	+$57.5M	+45.1%	Oct 1, 2022	Dec 31, 2022	10-K	2023-03-16
Q3 2022	$510M	$127M	+$13.4M	+11.8%	Jul 1, 2022	Sep 30, 2022	10-Q	2022-11-08
Q2 2022	$496M	$130M	+$15.8M	+13.8%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-08-14
Q1 2022	$480M	$125M	+$26.1M	+26.3%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-15
Q4 2021	$454M	$128M	+$45.7M	+55.7%	Oct 1, 2021	Dec 31, 2021	10-K	2022-03-11
Q3 2021	$409M	$113M	+$18.6M	+19.6%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-08
Q2 2021	$390M	$114M	+$57.3M	+101%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-15
Q1 2021	$333M	$99.2M	+$48.3M	+94.9%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-05
Q4 2020	$285M	$82M	+$36.4M	+79.8%	Oct 1, 2020	Dec 31, 2020	10-K	2022-03-11
Q3 2020	$248M	$94.9M	+$35.8M	+60.6%	Jul 1, 2020	Sep 30, 2020	10-K	2022-03-11
Q2 2020	$212M	$56.7M	-$103K	-0.18%	Apr 1, 2020	Jun 30, 2020	10-K	2022-03-11
Q1 2020	$212M	$50.9M	-$78.4M	-60.7%	Jan 1, 2020	Mar 31, 2020	10-K	2022-03-11
Q4 2019	$291M	$45.6M	-$2.92M	-6.01%	Oct 1, 2019	Dec 31, 2019	10-K	2021-02-19
Q3 2019	$294M	$59.1M	+$7.05M	+13.6%	Jul 1, 2019	Sep 30, 2019	10-K	2021-02-19
Q2 2019	$287M	$56.8M	+$24.6M	+76.1%	Apr 1, 2019	Jun 30, 2019	10-K	2021-02-19
Q1 2019	$262M	$129M	+$90.5M	+233%	Jan 1, 2019	Mar 31, 2019	10-K	2021-02-19
Q4 2018	$172M	$48.5M	-$6.68M	-12.1%	Oct 1, 2018	Dec 31, 2018	10-K	2020-03-03
Q3 2018	$178M	$52M	+$27M	+108%	Jul 1, 2018	Sep 30, 2018	10-K	2020-03-03
Q2 2018	$151M	$32.3M	+$14.2M	+78.1%	Apr 1, 2018	Jun 30, 2018	10-K	2020-03-03
Q1 2018	$137M	$38.8M	+$10.6M	+37.6%	Jan 1, 2018	Mar 31, 2018	10-K	2020-03-03
Q4 2017	$127M	$55.2M	+$33.4M	+153%	Oct 1, 2017	Dec 31, 2017	8-K	2019-06-17
Q3 2017	$93.1M	$25M	+$10.5M	+72.5%	Jul 1, 2017	Sep 30, 2017	8-K	2019-06-17
Q2 2017	$82.6M	$18.1M	-$27.5M	-60.3%	Apr 1, 2017	Jun 30, 2017	8-K	2019-06-17
Q1 2017	$110M	$28.2M	+$5.2M	+22.6%	Jan 1, 2017	Mar 31, 2017	8-K	2019-06-17
Q4 2016	$105M	$21.8M	+$2.83M	+14.9%	Oct 1, 2016	Dec 31, 2016	10-K	2018-03-16
Q3 2016	$102M	$14.5M	-$22.2M	-60.6%	Jul 1, 2016	Sep 30, 2016	10-K	2018-03-16
Q2 2016	$124M	$45.6M	+$33.9M	+290%	Apr 1, 2016	Jun 30, 2016	10-K	2018-03-16
Q1 2016	$90.4M	$23M	+$11.8M	+106%	Jan 1, 2016	Mar 31, 2016	10-K	2018-03-16
Q4 2015	$78.6M	$19M	+$8.45M	+80.2%	Oct 1, 2015	Dec 31, 2015	10-K/A	2017-03-27
Q3 2015	$70.1M	$36.7M	+$28.3M	+337%	Jul 1, 2015	Sep 30, 2015	10-K/A	2017-03-27
Q2 2015	$41.8M	$11.7M	+$2.94M	+33.5%	Apr 1, 2015	Jun 30, 2015	10-K/A	2017-03-27
Q1 2015	$38.9M	$11.2M	+$304K	+2.8%	Jan 1, 2015	Mar 31, 2015	10-K/A	2017-03-27
Q4 2014	$38.6M	$10.5M			Oct 1, 2014	Dec 31, 2014	10-K	2016-03-15
Q3 2014		$8.41M	+$5.02M	+148%	Jul 1, 2014	Sep 30, 2014	10-K	2016-03-15
Q2 2014		$8.77M			Apr 1, 2014	Jun 30, 2014	10-K	2016-03-15
Q1 2014		$10.9M			Jan 1, 2014	Mar 31, 2014	10-K	2016-03-15
Q3 2013		$3.39M			Jul 1, 2013	Sep 30, 2013	10-Q	2014-11-04

* An asterisk sign (*) next to the value indicates that the value is likely invalid.